Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial
E Massarelli, W William, F Johnson, M Kies… - JAMA …, 2019 - jamanetwork.com
Importance In recurrent human papilloma virus (HPV)–driven cancer, immune checkpoint
blockade with anti–programmed cell death 1 (PD-1) antibodies produces tumor regression
in only a minority of patients. Therapeutic HPV vaccines have produced strong immune
responses to HPV-16, but vaccination alone has been ineffective for invasive cancer.
Objective To determine whether the efficacy of nivolumab, an anti–PD-1 immune checkpoint
antibody, is amplified through treatment with ISA 101, a synthetic long-peptide HPV-16 …
blockade with anti–programmed cell death 1 (PD-1) antibodies produces tumor regression
in only a minority of patients. Therapeutic HPV vaccines have produced strong immune
responses to HPV-16, but vaccination alone has been ineffective for invasive cancer.
Objective To determine whether the efficacy of nivolumab, an anti–PD-1 immune checkpoint
antibody, is amplified through treatment with ISA 101, a synthetic long-peptide HPV-16 …